Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

FS Development (FSDC) Competitors

FS Development logo

FSDC vs. LSEA, GWAC, YSAC, FOLD, VRNA, ZLAB, HCM, ACAD, MOR, and AMRX

Should you be buying FS Development stock or one of its competitors? The main competitors of FS Development include Landsea Homes (LSEA), Good Works Acquisition (GWAC), Yellowstone Acquisition (YSAC), Amicus Therapeutics (FOLD), Verona Pharma (VRNA), Zai Lab (ZLAB), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), MorphoSys (MOR), and Amneal Pharmaceuticals (AMRX).

FS Development vs.

Landsea Homes (NASDAQ:LSEA) and FS Development (NASDAQ:FSDC) are both small-cap finance companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.

In the previous week, Landsea Homes had 9 more articles in the media than FS Development. MarketBeat recorded 9 mentions for Landsea Homes and 0 mentions for FS Development. Landsea Homes' average media sentiment score of 0.23 beat FS Development's score of 0.00 indicating that Landsea Homes is being referred to more favorably in the media.

Company Overall Sentiment
Landsea Homes Neutral
FS Development Neutral

Landsea Homes received 21 more outperform votes than FS Development when rated by MarketBeat users.

CompanyUnderperformOutperform
Landsea HomesOutperform Votes
21
38.89%
Underperform Votes
33
61.11%
FS DevelopmentN/AN/A

Landsea Homes has a net margin of 1.82% compared to FS Development's net margin of 0.00%. Landsea Homes' return on equity of 6.96% beat FS Development's return on equity.

Company Net Margins Return on Equity Return on Assets
Landsea Homes1.82% 6.96% 2.92%
FS Development N/A N/A N/A

83.0% of Landsea Homes shares are owned by institutional investors. Comparatively, 89.8% of FS Development shares are owned by institutional investors. 51.0% of Landsea Homes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Landsea Homes has higher revenue and earnings than FS Development.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Landsea Homes$1.21B0.32$29.24M$0.7214.99
FS DevelopmentN/AN/AN/AN/AN/A

Landsea Homes currently has a consensus target price of $15.50, suggesting a potential upside of 43.65%. Given Landsea Homes' stronger consensus rating and higher probable upside, equities analysts plainly believe Landsea Homes is more favorable than FS Development.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Landsea Homes
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
FS Development
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Landsea Homes beats FS Development on 11 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FSDC vs. The Competition

MetricFS DevelopmentPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$789.26M$7.03B$5.37B$8.88B
Dividend YieldN/A8.03%5.06%4.03%
P/E RatioN/A11.50127.4017.46
Price / SalesN/A347.551,258.8592.75
Price / CashN/A49.2239.3636.42
Price / BookN/A9.076.285.86
Net IncomeN/A$154.14M$119.59M$225.15M

FS Development Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FSDC
FS Development
N/A$63.06
-0.3%
N/A+30.2%$789.26MN/A0.00N/A
LSEA
Landsea Homes
4.524 of 5 stars
$10.50
-5.3%
N/A+15.6%$402.38M$1.21B14.58380
GWAC
Good Works Acquisition
N/A$7.43
+3.8%
N/A+146.6%$159.58MN/A0.002Gap Up
High Trading Volume
YSAC
Yellowstone Acquisition
N/AN/AN/AN/A$147.38MN/A0.003
FOLD
Amicus Therapeutics
4.6224 of 5 stars
$10.49
-1.9%
N/A+1.0%$3.19B$399.36M-30.85480Analyst Forecast
Short Interest ↓
VRNA
Verona Pharma
2.4178 of 5 stars
$39.00
-2.2%
N/A+159.3%$3.19B$460,000.00-20.3130
ZLAB
Zai Lab
3.2898 of 5 stars
$28.96
-6.9%
N/A+10.8%$3.10B$266.72M-9.462,175News Coverage
Gap Down
HCM
HUTCHMED
1.7143 of 5 stars
$17.48
-0.9%
N/A-8.0%$3.07B$838M0.001,988Short Interest ↓
Gap Down
ACAD
ACADIA Pharmaceuticals
4.1104 of 5 stars
$17.93
-1.9%
N/A-21.5%$3.04B$726.44M22.99510Short Interest ↑
Analyst Revision
MOR
MorphoSys
0.0778 of 5 stars
$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
AMRX
Amneal Pharmaceuticals
2.9861 of 5 stars
$9.25
+0.5%
N/A+110.7%$2.85B$2.39B-13.607,700Analyst Forecast
Short Interest ↓

Related Companies and Tools


This page (NASDAQ:FSDC) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners